| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Vesencumab (anti-NRP1)
CAS:1205533-60-3
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14224
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Vesencumab
CAS:1205533-60-3
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Vesencumab
CAS:1205533-60-3
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Vesencumab
CAS:1205533-60-3
Package:1mg/RMB 2880;5mg/RMB 6570;10mg/RMB 8860
|
|
| | Vesencumab Basic information |
| Product Name: | Vesencumab | | Synonyms: | Vesencumab;Research Grade Vesencumab (DHA30101);Research Grade Vesencumab;Vesencumab (anti-NRP1) | | CAS: | 1205533-60-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Vesencumab Structure]() |
| | Vesencumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Vesencumab Usage And Synthesis |
| Uses | Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer[1][2]. | | in vivo | Vesencumab (10 mg/kg, ip, twice a week for 7 weeks) exhibits antitumor effect in mouse SUM159 orthotopic xenograft models[3]. | Animal Model: | Mouse SUM159 orthotopic xenograft models[3] | | Dosage: | 10 mg/kg | | Administration: | ip, twice a week for 7 weeks | | Result: | Inhibited tumor volume and weight. |
| | References | [1] Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
[2] Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362. DOI:10.3390/cells11213362 |
| | Vesencumab Preparation Products And Raw materials |
|